Findings

What do systematic reviews say?

4,752 questions · 6,648 findings · 688 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,125 · 16.9%GRADE not reported 670 · 10.1%Very low 1,796 · 27%Low 1,685 · 25.3%Moderate 1,075 · 16.2%High 297 · 4.5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Tumour response measures · people with liver metastases

1 finding from 1 review

Cryotherapy for liver metastases 2019 · Cochrane Headline outcomes only
30
69 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher progression‐free survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.43 [1.06, 1.93]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Quality of life ‐ not reported · women with advanced or recurrent endometrial cancer

The review found no eligible studies for this question.

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

mTOR inhibitors vs chemotherapy/hormone therapy

Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors probably leads to lower progression‐free survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (moderate certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 0.53 [0.31, 0.91]
1 study · 95 participants
Moderate

mTOR inhibitors vs chemotherapy/hormone therapy

Haematological toxicities ‐ Anaemia · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in haematological toxicities ‐ Anaemia compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 1.42 [0.83, 2.44]
2 studies · 357 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Skin toxicities ‐ Mucositis · women with advanced or recurrent endometrial cancer

mTOR inhibitors may leads to higher skin toxicities ‐ Mucositis compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 10.42 [1.34, 80.74]
2 studies · 357 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Respiratory toxicity ‐ Interstitial pneumonitis · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in respiratory toxicity ‐ Interstitial pneumonitis compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 7.36 [0.88, 61.52]
2 studies · 357 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Overall survival ‐ first‐line studies · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in overall survival: first‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.32 [0.98, 1.78]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Overall survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in overall survival: second/third‐line trials ( compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
HR 1.06 [0.7, 1.61]
1 study · 130 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Objective response rate: first‐line trial · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in objective response rate: first‐line trial compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 0.93 [0.75, 1.17]
1 study · 231 participants
Low

mTOR inhibitors vs chemotherapy/hormone therapy

Objective response rate: second/third‐line trials · women with advanced or recurrent endometrial cancer

mTOR inhibitors showed no clear difference in objective response rate: second/third‐line trials compared with chemotherapy/hormone therapy (low certainty).

1 finding from 1 review

PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer 2019 · Cochrane Headline outcomes only
RR 0.22 [0.01, 4.4]
1 study · 61 participants
Low

Long‐term GnRH agonist therapy vs no additional therapy

Live birth rate · patients with endometriosis prior to standard IVF/ICSI

It is very uncertain whether long‐term GnRH agonist therapy changes live birth rate compared with no additional therapy (very low certainty).

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
RR 0.48 [0.26, 0.87]
1 study · 147 participants
Very low

Long‐term GnRH agonist therapy vs no additional therapy

Complication rate · patients with endometriosis prior to standard IVF/ICSI

It is very uncertain whether long‐term GnRH agonist therapy changes complication rate compared with no additional therapy (very low certainty).

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
Peto OR 1.23 [0.37, 4.14]
3 studies · 318 participants
Very low

Long‐term GnRH agonist therapy vs no additional therapy

Clinical pregnancy rate · patients with endometriosis prior to standard IVF/ICSI

It is very uncertain whether long‐term GnRH agonist therapy changes clinical pregnancy rate compared with no additional therapy (very low certainty).

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
RR 1.13 [0.91, 1.41]
6 studies · 552 participants
Very low

Long‐term GnRH agonist therapy vs no additional therapy

Multiple pregnancy rate · patients with endometriosis prior to standard IVF/ICSI

It is very uncertain whether long‐term GnRH agonist therapy changes multiple pregnancy rate compared with no additional therapy (very low certainty).

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
Peto OR 0.14 [0.04, 0.56]
2 studies · 208 participants
Very low

Long‐term GnRH agonist therapy vs no additional therapy

Miscarriage · patients with endometriosis prior to standard IVF/ICSI

It is very uncertain whether long‐term GnRH agonist therapy changes miscarriage rate compared with no additional therapy (very low certainty).

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
Peto OR 0.45 [0.1, 2]
2 studies · 208 participants
Very low

Long‐term GnRH agonist therapy vs no additional therapy

Number of oocytes retrieved · patients with endometriosis prior to standard IVF/ICSI

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 385 participants
Very low

Long‐term GnRH agonist therapy vs no additional therapy

Mean number of embryos · patients with endometriosis prior to standard IVF/ICSI

1 finding from 1 review

Long‐term GnRH agonist therapy before in vitro fertilisation (IVF) for improving fertility outcomes in women with… 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 267 participants
Very low

Combined oral contraceptive pill vs placebo or no treatment

Self‐reported pain (dysmenorrhoea) at the end of treatment (continuous data): dysmenorrhoea at 6 months' · women with endometriosis

2 findings from 1 review

Oral contraceptives for pain associated with endometriosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 96 participants
Very low
Oral contraceptives for pain associated with endometriosis 2018 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 327 participants
Very low

Combined oral contraceptive pill vs placebo or no treatment

Self‐reported pain: menstrual pain reduction from baseline to end of treatment · women with endometriosis

1 finding from 1 review

Oral contraceptives for pain associated with endometriosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 169 participants
Very low